Selective serotonin reuptake inhibitor effects on neural biomarkers of perinatal depression

Jodi L Pawluski (1, 2) , Ursula Brain (3) , Geoffrey L Hammond (3) , Tim F Oberlander (3)

1 Irset - Institut de recherche en santé, environnement et travail
2 EHESP - École des Hautes Études en Santé Publique [EHESP]
3 UBC - University of British Columbia

The effect of perinatal selective serotonin reuptake inhibitors (SSRIs) on brain-derived neurotrophic factor (BDNF) and S100 calcium binding protein B (S100B) has not been investigated. Using a cohort of 86 pregnant women, we found that SSRIs significantly increase BDNF levels in late pregnancy and that S100B, but not BDNF, is associated with maternal depression in SSRI-treated women only. This shows that serum S100B could be a unique biomarker to determine efficacy of SSRIs during gestation.

Keywords: Motherhood; Anxiety; Neuroplasticity; Antidepressants; Depression; Gestation

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Human health and pathology; Psychiatrics and mental health; Life Sciences [q-bio]; Santé publique et épidémiologie

Jodi L Pawluski, Ursula Brain, Geoffrey L Hammond, Tim F Oberlander. Selective serotonin reuptake inhibitor effects on neural biomarkers of perinatal depression. Archives of Women's Mental Health, 2019, 22 (3), pp.431-435. ⟨10.1007/s00737-018-0931-1⟩. ⟨hal-01976469⟩